Federal Register · Regulatory notice
Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.
Follow PFE- Became public
- Jun 8, 2026
- Event / period date
- Not stated
- Collected
- Nov 7, 2026, 7:16 PM EST
Why this is connected
The source explicitly mentions PFIZER INC. A mention alone does not establish a financial benefit.
Source evidence
Read the source excerpt or record
um. 2.5 mg Base/mL; Injection. METHOTREXTATE EQ 20 mg Base/2 LPF AND mL (EQ 10 mg METHOTREXATE Base/mL); EQ 20 PRESERVATIVE mg Base/Vial; FREE. EQ 25 mg Base/ mL; EQ 25 mg Base/mL; EQ 2.5 grams (g) Base/ 100 mL (EQ 25 mg Base/mL); EQ 50 mg Base/ Vial; EQ 100 mg Base/Vial; EQ 1g Base/Vial. NDA 012250.......... CARBOCAINE....... Mepivacaine 1%; 1.5%; 2%.... Injectable; Hospira, Inc. Hydrochloride. Injection. NDA 016909.......... LIDEX............ Fluocinonide..... 0.05%........... Ointment; Alvogen, Inc. Topical. NDA 017010.......... DESONIDE......... Desonide......... 0.05%........... Cream; Topical.. Padagis LLC. NDA 017735.......... MODICON 28....... Ethinyl 0.035 mg; 0.5 mg Tablet; Oral-28. Janssen Estradiol; Pharmaceuticals Norethindrone. , Inc. NDA 018337.......... ACETAMINOPHEN.... Acetaminophen.... 650 mg.......... Suppository; Taro Rectal. Pharmaceutical Industries Ltd. NDA 019260.......... PSORCON.......... Diflorasone 0.05%........... Ointment; Pfizer Inc. Diacetate. Topical. NDA 019487 P001..... IMODIUM A-D...... Loperamide 1 mg/5 mL....... Solution; Oral.. Kenvue Brands Hydrochloride. LLC. NDA 020021.......... SUDAFED 24 HOUR.. Pseudoephedrine 240 mg.......... Tablet, Extended Kenvue Brands Hydrochloride. Release; Oral. LLC. NDA 020449.......... TAXOTERE......... Docetaxel........ 20 mg/mL (20 mg/ Injectable; Sanofi-Aventis mL); 80 mg/4 mL Injection. U.S. LLC. (20 mg
Price change after we could observe it
+0.75% PFE
Adjusted closing prices from Nov 9, 2026 to Nov 11, 2026. SPY changed 0.95% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in PFE
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 25, 2026 · disclosed Oct 7, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 11, 2026 · disclosed Oct 7, 2026 · Dependent
- Oct 7, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
$1K–$15K · Traded Nov 26, 2024 · disclosed Aug 7, 2026 · filed 619 days later
Got $3K from the company’s PAC - Jul 21, 2026$50K–$100K
Sen. Alan Armstrong (R-OK)
$50K–$100K · Traded Mar 24, 2026 · disclosed Jul 21, 2026 · filed 119 days later
Committee overlap: HELP - Jul 16, 2026$15K–$50K
Sen. Tommy Tuberville (R-AL)
$15K–$50K · Traded Jun 8, 2026 · disclosed Jul 16, 2026 · Joint
Committee overlap: HELP - May 11, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.